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What does serum fibroblast 
growth factor 23 do in 
hemodialysis patients?
M Emmett1
Fibroblast growth factor 23 (FGF-23) is a phosphate-regulating 
substance largely produced by osteocytes. Its major action, in normal 
subjects, is the inhibition of Na-coupled reabsorption of inorganic 
phosphate in the renal proximal tubule. FGF-23 levels increase 
markedly in dialysis patients. Why do the FGF-23 levels increase in these 
patients, and do they have any physiologic or pathophysiologic effects?
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Fibroblast growth factor 23 (FGF-
23) levels increase as kidney function 
declines and are very high in hemodial-
ysis patients.1,2 What factors are respon-
sible for the elevation, and do the high 
FGF-23 levels in these patients have 
biologic eﬀects? The study by Ureña-
Torres et al.3 (this issue) addresses 
these questions. This group measured 
pre- and postdialysis FGF-23 levels in 
a large cohort of hemodialysis patients 
and looked for correlations between 
those levels and predialysis inorganic 
phosphate (Pi) concentrations, Ca × Pi 
product, levels of parathyroid hormone 
(PTH) and vitamin D, and administered 
dose of vitamin D analogues. They also 
looked for FGF-23 relationships with 
bone synthetic and bone resorptive 
markers and with measurements of 
bone density.
What is FGF-23, and what do we cur-
rently understand about the function 
and regulation of this protein? During 
the 1990s, studies of several heredi-
tary and sporadic forms of osteomala-
cia/rickets, all characterized by severe 
hypophosphatemia and inappropriate 
phosphaturia, led to the discovery of a 
group of Pi-regulating proteins called 
phosphatonins. One of these disorders 
is tumor-induced osteomalacia (TIO), a 
rare disease associated with mesenchy-
mal tumors that has the following clini-
cal and biochemical manifestations: 
(1) hypophosphatemia;
(2) renal Pi wasting;
(3) low 1,25(OH)2-vitamin D3 levels;
(4)  normal to slightly low serum 
calcium concentration;
(5) osteomalacia;
(6)  resolution of all the abnormalities 
after resection of a soft-tissue 
neoplasm, which is usually small 
and not malignant.
It was found that these tumors secreted 
several diﬀerent proteins that inhibited 
renal tubule Pi transport and thereby 
caused inappropriate phosphaturia.4,5 
The most potent and best characterized 
of these phosphatonin proteins is a 25-
kilodalton (227-amino acid) member of 
the ﬁbroblast growth factor protein fam-
ily, designated FGF-23.6 Other proteins 
that aﬀect phosphorus metabolism were 
also isolated from these tumors. They 
include frizzled-related protein-4 (FRP-
4), matrix extracellular phosphoglyco-
protein (MEPE), and FGF-7.5,7
The study of two hereditary diseases 
with biochemical and clinical mani-
festations that were very similar to 
those that characterize tumor-induced 
osteomalacia  yielded addit ional 
insights. Autosomal dominant hypo-
phosphatemic rickets was shown to be 
due to a mutation in the FGF-23 gene 
that results in the synthesis of a hyper-
stable form of this protein.5,7 Another 
phenotypically similar disorder is X-
linked hypophosphatemic rickets, which 
is caused by a mutation of the PHEX 
gene (phosphate-regulating gene with 
homologies to endopeptidases on the X 
chromosome). PHEX is a Zn-metalloen-
dopeptidase that directly catabolizes 
FGF-23 and/or inhibits FGF-23 syn-
thesis.5,7 Consequently, reduced activ-
ity of PHEX increases FGF-23 levels. All 
three disorders are therefore associated 
with inappropriately increased FGF-23 
levels. In contrast, absence or deﬁciency 
of FGF-23 activity causes hyperphos-
phatemia and soft-tissue calciﬁcation.
A number of FGF-23-speciﬁc receptors 
have been identified, but it remains 
uncertain which receptor, or combi-
nation of receptors, is responsible for 
FGF-23 eﬀects on Pi metabolism.8 One 
other molecule intimately involved in 
the activation of FGF-23 receptors is a 
transmembrane protein called klotho. 
A normal klotho protein is required for 
FGF-23 to inhibit phosphate transport.8 
Consequently, klotho defects produce a 
phenotype similar to disorders associated 
with inadequate or absent FGF-23 levels.
Figure 1 summarizes our current 
understanding of FGF-23 regulation 
and physiology. It is believed that Pi 
ingestion, an expanded Pi pool, and/
or hyperphosphatemia causes FGF-23 
release from skeletal osteocytes and 
osteoblasts.5,7,9 1,25(OH)2-vitamin D3 
also stimulates FGF-23 synthesis. (In 
addition, FGF-23 is also synthesized 
in the ventrolateral thalamic nuclei, 
the thymus, and lymph nodes, where 
it probably has a number of yet-to-be-
characterized local eﬀects. However, cir-
culating FGF-23 is principally of skeletal 
origin.) When FGF-23 interacts with its 
kidney receptors, and klotho, it inhibits 
the principal Na-coupled Pi cotrans-
porter in the proximal tubule (Na-Pi 
type IIa, or NPt2) and causes phospha-
turia. FGF-23 also inhibits 1α-vitamin 
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D3 hydroxylase, which reduces the syn-
thesis of 1,25(OH)2-vitamin D3 and 
thereby decreases small-bowel absorp-
tion of calcium and Pi. These effects 
all seem physiologically appropriate. 
Oral Pi loads would thereby reduce Pi 
absorption in the gastrointestinal tract 
and increase renal Pi excretion. How-
ever, the FGF-23 response to ingested 
Pi does not seem to be rapid; rather, its 
action occurs more slowly and chroni-
cally.5,9 Several other potential FGF-23 
eﬀects (shown as dotted lines in Fig-
ure 1) are less well deﬁned or proven. 
FGF-23 may increase the synthesis and 
release of PTH, and some evidence sug-
gests that PTH may increase FGF-23 
levels. FGF-23 may also directly depress 
bone mineralization.9
It seems clear that the high FGF-23 
levels in patients with tumor-induced 
osteomalacia, autosomal dominant 
hypophosphatemic rickets, and X-
linked hypophosphatemic rickets are 
largely responsible for hypophos-
phatemia, inappropriate phosphaturia, 
and reduced active vitamin D levels. 
However, it remains unclear whether 
the bone disease that develops in these 
patients is a direct pathologic eﬀect of 
FGF-23 hyperactivity or is due to low 
serum Pi, low active vitamin D levels, 
or all three abnormalities.
Many questions also exist regarding 
the high FGF-23 levels that are meas-
ured in dialysis patients. Are they due 
to reduced clearance of the native pro-
tein, or reduced clearance of active and/
or inactive FGF-23 metabolites, or do 
they represent an exaggerated response 
to the pathophysiologic milieu of kidney 
failure (hyperphosphatemia, high PTH 
levels, exogenous vitamin D, and so on)? 
Furthermore, do the high FGF-23 lev-
els in dialysis patients have important 
biologic eﬀects? Do they block the acti-
vation, or tissue eﬀects, of vitamin D, 
stimulate PTH secretion, and/or have 
a direct impact on bone mineralization 
and renal osteodystrophy?
The study by Ureña-Torres et al.3 
reports that the FGF 23 levels in dialysis 
patients are between 10 and 600 times 
higher than the normal range and 
strongly correlate with predialysis Pi 
levels and the Ca × P product. These 
data conﬁrm previous reports. FGF-23 
levels did not fall during the dialysis 
procedure; this suggests that the dial-
ysis membranes used in this group of 
patients did not clear the protein and/
or its metabolites. In contrast to sev-
eral previous reports, FGF-23 levels in 
these dialysis patients did not correlate 
with PTH or vitamin D levels. Nor did 
there seem to be any relation to vitamin 
D dosage. Of most importance, Ureña-
Torres et al.3 found no correlation 
between FGF-23 levels and bone min-
eral density or several markers of bone 
turnover — bone-speciﬁc alkaline phos-
phatase (a synthetic marker) and the 
CrossLaps assay (a resorption marker). 
This suggests that the high FGF-23 lev-
els in dialysis patients may be without 
important biologic skeletal eﬀects. This 
study therefore suggests that the dotted 
lines in Figure 1 are of minor impor-
tance in hemodialysis patients.
However, an important caveat must 
be emphasized: the circulating FGF-
23 molecule is normally cleaved, and 
at least several cleavage products (N- 
and C-terminal peptides) circulate.10 
Some immunoassays measure only 
intact FGF-23 molecules, whereas oth-
ers also react with C-terminal peptides. 
Although several studies indicate that 
these amino- and carboxy-fragments 
are inactive, some biologically active 
fragments have been identiﬁed.10 The 
current state of knowledge regarding 
FGF-23 immunoassays, the biologic role 
of the intact protein, and the potential 
importance of various metabolic frag-
ments is analogous to our understanding 
15–20 years ago of PTH immunoassays 
and the clinical impact of intact PTH 
and PTH fragments in dialysis patients. 
Ureña-Torres et al.3 did use a carboxy-
terminal assay that reacts with both 
intact molecules and C-terminal frag-
ments. As FGF-23 assays improve and 
become better deﬁned and the poten-
tial role of both precursor molecules 
and metabolic fragments of FGF-23 is 
worked out, the interpretation of these 
data may need to be revised.
Figure 1 | The regulation and action of FGF-23. Hyperphosphatemia, inorganic phosphate 
(Pi) loads, and/or an increased Pi pool cause FGF-23 to be released from skeletal osteocytes and 
osteoblasts. 1,25(OH)2-vitamin D3 also stimulates release of FGF-23. The major known effects 
of FGF-23 are inhibition of Na-Pi cotransport in the kidney and the resultant phosphaturia and 
inhibition of 1α-vitamin D3 hydroxylase, which reduces levels of 1,25(OH)2-vitamin D3. Reduced 
active vitamin D levels decrease gastrointestinal Pi (and calcium) absorption. The action of FGF-23 
requires interaction with specific receptors and a transmembrane protein called klotho. The dotted 
lines indicate several other possible FGF-23 effects. The protein may stimulate parathyroid function, 
and it also may directly impair bone mineralization. PTH may also stimulate FGF-23 secretion.
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Dual role of the activated 
epidermal growth factor 
receptor in renal tubular cells 
during stress
I Arany1
The paper by Sarro et al. raises the therapeutically important 
possibility that activation of the epidermal growth factor receptor 
(EGFR) after proximal tubule injury serves an unexpected death 
function and the EGFR-mediated survival signaling can be restored 
by identification of parallel and interacting pathways.
Kidney International (2008) 72, 5–7. doi:10.1038/sj.ki.5002583
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In this issue of Kidney International, Sarro 
et al.1 demonstrate that nephrotoxic-
ity induced by the immunosuppressor 
cyclosporine A (CsA) is intimately linked 
to the activated epidermal growth factor 
receptor (EGFR) in mouse proximal tubule 
cells in vitro. The paper calls attention to a 
long-disregarded fact: the activated EGFR 
could participate in cell death, in addition 
to its more widely accepted role in enhanc-
ing the regeneration of the injured seg-
ments of the kidney2 or mediating survival 
during oxidative stress in vitro.3
The EGFR is present in the proximal 
tubules of the kidney: it is activated dur-
ing ischemia/reperfusion injury in vivo 
and by severe oxidative stress in vitro, 
with both conditions resulting in necrotic 
death.4 By contrast, moderate oxidative 
stress-induced EGFR activation is linked 
to cell survival.4 Cisplatin also activates 
the EGFR in renal proximal tubular 
cells in vitro, and the activated recep-
tor is involved in cell death rather than 
survival under these conditions.5 These 
studies suggest dual roles of the EGFR: 
the activated EGFR promotes either sur-
vival or death depending on either the 
intensity or the duration of stress or the 
particular stress involved; the outcome 
of EGFR activation is molded by down-
stream signaling events that depend on 
the type or intensity of the stress.
How does this dual role of the 
activated EGFR occur? EGFR-mediated 
survival signaling involves activation of 
ras and extracellular signal-regulated 
kinase (ERK)3 and their downstream 
target the transcription factor cAMP-
responsive element-binding protein 
(CREB)4 in renal epithelial cells in vitro. 
One possibility is the activation of paral-
lel signaling events; the balance between 
those signaling events determines 
whether cells survive or die. In the study 
by Sarro et al.,1 CsA treatment activated 
both ERK and phosphatidylinositol-3′-
kinase (PI3K) in an EGFR-dependent 
manner; however, only the activated 
PI3K was associated with cell death. 
Because the activated ERK generally 
participates in survival signaling during 
stress conditions,6 it is plausible that the 
pro-death pathway is supported over the 
pro-survival ERK by CsA. It is unclear, 
though, whether the activated ERK is 
indeed pro-survival in this model. Many 
studies suggest another somewhat simi-
lar scenario, that a balance between spe-
ciﬁc members of the mitogen-activated 
protein kinase (MAPK) family deter-
mines cell fate; unopposed activation 
of c-Jun NH2-terminal kinase (JNK) 
during ischemia/reperfusion injury 
in vivo7 or H2O2-mediated oxidative 
stress in vitro8 is linked to cell death. By 
contrast, the presence of activated ERK 
favors survival even in the presence of 
death signals, that is, JNK activation. 
Opposing roles of diﬀerent MAPKs in 
survival or death during stress are well 
established.6
Another possibility is that the acti-
vated EGFR is uncoupled from its 
downstream components by parallel 
signaling events, resulting in inhibition 
of survival signaling and subsequent cell 
